Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Terry J Smith

Showing results (1-10 of 232) with videos related to

Pageof 24
Sort By:
The Journal of Clinical Endocrinology and Metabolism|May 8, 2007
B cell depletion in Graves' disease: the right answer to the wrong question?Terry J Smith
European Journal of Endocrinology|October 7, 2021
Comment on the 2021 EUGOGO Clinical Practice Guidelines for the Medical Management of Graves' OrbitopathyTerry J Smith
Annual Review of Pharmacology and Toxicology|July 26, 2018
Challenges in Orphan Drug Development: Identification of Effective Therapy for Thyroid-Associated OphthalmopathyTerry J Smith
Frontiers in Endocrinology|June 21, 2021
Insulin-Like Growth Factor Pathway and the ThyroidTerry J Smith
Frontiers in Endocrinology|January 4, 2021
Teprotumumab as a Novel Therapy for Thyroid-Associated OphthalmopathyTerry J Smith
F1000Research|May 11, 2018
New advances in understanding thyroid-associated ophthalmopathy and the potential role for insulin-like growth factor-I receptorTerry J Smith
The Journal of Clinical Endocrinology and Metabolism|November 8, 2022
Understanding Pathogenesis Intersects With Effective Treatment for Thyroid Eye DiseaseTerry J Smith
Expert Opinion on Orphan Drugs|October 31, 2019
Is there potential for the approval of monoclonal antibodies to treat thyroid-associated ophthalmopathy?Terry J Smith
Expert Review of Ophthalmology|June 13, 2017
Rationale for therapeutic targeting insulin-like growth factor-1 receptor and bone marrow-derived fibrocytes in thyroid-associated ophthalmopathyTerry J Smith
Ophthalmology|February 13, 2024
Re: Shah et al.: Teprotumumab-related adverse events in thyroid eye disease: a multicenter study (Ophthalmology. 2024;131:458-467)Terry J Smith
Pageof 24

Showing results (1-10 of 232) with videos related to

Sort By:
Pageof 24
The Journal of Clinical Endocrinology and Metabolism|May 8, 2007
B cell depletion in Graves' disease: the right answer to the wrong question?Terry J Smith
European Journal of Endocrinology|October 7, 2021
Comment on the 2021 EUGOGO Clinical Practice Guidelines for the Medical Management of Graves' OrbitopathyTerry J Smith
Annual Review of Pharmacology and Toxicology|July 26, 2018
Challenges in Orphan Drug Development: Identification of Effective Therapy for Thyroid-Associated OphthalmopathyTerry J Smith
Frontiers in Endocrinology|June 21, 2021
Insulin-Like Growth Factor Pathway and the ThyroidTerry J Smith
Frontiers in Endocrinology|January 4, 2021
Teprotumumab as a Novel Therapy for Thyroid-Associated OphthalmopathyTerry J Smith
F1000Research|May 11, 2018
New advances in understanding thyroid-associated ophthalmopathy and the potential role for insulin-like growth factor-I receptorTerry J Smith
The Journal of Clinical Endocrinology and Metabolism|November 8, 2022
Understanding Pathogenesis Intersects With Effective Treatment for Thyroid Eye DiseaseTerry J Smith
Expert Opinion on Orphan Drugs|October 31, 2019
Is there potential for the approval of monoclonal antibodies to treat thyroid-associated ophthalmopathy?Terry J Smith
Expert Review of Ophthalmology|June 13, 2017
Rationale for therapeutic targeting insulin-like growth factor-1 receptor and bone marrow-derived fibrocytes in thyroid-associated ophthalmopathyTerry J Smith
Ophthalmology|February 13, 2024
Re: Shah et al.: Teprotumumab-related adverse events in thyroid eye disease: a multicenter study (Ophthalmology. 2024;131:458-467)Terry J Smith
Pageof 24